Travere Therapeutics Inc (NAS:TVTX)
$ 6.16 -0.18 (-2.84%) Market Cap: 468.95 Mil Enterprise Value: 431.93 Mil PE Ratio: 0 PB Ratio: 6.33 GF Score: 54/100

Retrophin, Inc. - Special Call Transcript

Aug 22, 2019 / 12:30PM GMT
Release Date Price: $13.56 (-22.07%)
Operator

Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Retrophin Inc. Phase III FORT Study Top Line Results Call. (Operator Instructions) As a reminder, this conference call is being recorded for replay purposes.

It is now my pleasure to hand the conference over to Mr. Chris Cline, Vice President, Investor Relations and Corporate Communications. Sir, you may begin.

Chris Cline
Retrophin, Inc. - VP of IR & Corporate Communications

Thank you, Brian. Good morning, everyone, and thank you for joining us on short notice to discuss the top line results from the FORT Study. In case any of you have not yet seen our press release outlining the results earlier this morning, it's available on our homepage of our Investors section of our website.

With me today are Dr. Eric Dube, our Chief Executive Officer; and Dr. Noah Rosenberg, our Chief Medical Officer; and Dr. Bill Rote, our Senior Vice President of Research and Development will also join us for the Q&A session. Eric and Noah will walk you through the top line result,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot